Caligan Partners LP Discloses New 10.4% Stake in SAB Biotherapeutics, Inc. (SABS)

On May 15, 2026, Caligan Partners LP and its Managing Partner, David Johnson, filed a Schedule 13G disclosing a significant new ownership stake in SAB Biotherapeutics, Inc. (SABS). The reporting persons acquired 7,697,207 shares of Common Stock, representing 10.4% of the company's outstanding shares based on 76,464,094 shares reported as of May 6, 2026. This filing marks a new position for the investment manager, as the previous ownership was 0.0%. Caligan Partners LP, a Delaware limited partnership, serves as the investment manager to various funds and accounts that hold these shares. The filing was made under Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. David Johnson, as the Managing Member of the general partner of Caligan, shares beneficial ownership of the reported shares. The principal business office for the reporting persons is located in New York, NY.